Siddiqi Syndrome

Key Findings

Finding 1 — Siddiqi syndrome is an autosomal recessive deafness–dystonia disorder caused by biallelic loss-of-function FITM2 variants

The founding description (PMID: 28067622, Zazo Seco et al., 2017) identified a homozygous nonsense mutation c.4G>T (p.Glu2*) in FITM2 in a consanguineous Pakistani family using genetic linkage plus whole-exome sequencing. The authors noted that "a homozygous nonsense mutation, c.4G>T (p.Glu2*), in FITM2 was identified. FITM2 and its paralog FITM1 constitute an evolutionary conserved protein family involved in partitioning of triglycerides into cellular lipid droplets." Independent replication reports subsequently confirmed that biallelic loss-of-function variants cause the syndrome (PMID: 30288795; PMID: 30214770).

A 2026 review reaffirmed the nosology and rarity: "Siddiqi syndrome is a rare autosomal recessive deafness-dystonia disorder caused by pathogenic variants in the FITM2 gene. To date, only 5 unrelated families have been reported in the literature carrying loss-of-function variants" (PMID: 41758270). FITM2 maps to 20q13.12 and encodes an ER-resident six-transmembrane protein.

Finding 2 — FITM2 encodes an ER acyl-CoA diphosphatase whose loss disrupts ER homeostasis

The molecular function of the FITM2 protein was resolved by Becuwe et al., 2020 (PMID: 32915949), who defined "the molecular function of the evolutionarily conserved ER protein FIT2 as a fatty acyl-coenzyme A (CoA) diphosphatase that hydrolyzes fatty acyl-CoA to yield acyl 4'-phosphopantetheine. This activity of FIT2, which is predicted to be active in the ER lumen, is required in yeast and mammalian cells for maintaining ER structure, protecting against ER stress."

In vivo confirmation came from Bond et al., 2023 (PMID: 36805337): "hepatocyte-specific Fitm2 knockout (FIT2-LKO) mice fed a chow diet exhibited elevated acyl-CoA levels, ER stress, and signs of liver injury." Earlier biochemical work established that FITM2 partitions triglyceride into lipid droplets by directly binding triglyceride but does not synthesize triacylglycerol (PMID: 22106267; PMID: 20520733). This dual role — enzymatic acyl-CoA turnover and physical lipid-droplet biogenesis — places FITM2 at the heart of ER lipid homeostasis.

Finding 3 — Disease identifiers and nosology

The disease is ultra-rare — approximately 10 patients from 5 families in the original tallies, expanding to ~10–15 patients across ~7 families by 2026 (Pakistan, USA, Germany, China, Russia, plus Iranian and Spanish cases in 2025–2026). All information is aggregated from individual case reports, not derived from EHR-based cohorts or disease registries.

Finding 4 — Core phenotype: deafness–dystonia–developmental regression with growth failure and ichthyosis

The core, near-constant features (present in essentially all reported patients) are:

The original description documented "progressive locomotor impairment, hearing loss and disturbed sensory functions" (PMID: 28067622). The Iranian sibling report emphasized the recurrent constellation of "early-onset sensorineural hearing loss, severe generalized dystonia, growth failure, and ichthyosis of the lower limbs" (PMID: 41113320). The 2026 neuroradiological report added spastic paraplegia and novel MRI findings, describing a patient with "deafness, intellectual disability, regression of motor skills and poor overall growth. Additionally, she presents with spastic paraplegia" (PMID: 41758270). A recognizable clinical triad is deafness + dystonia + ichthyosis. In the index Pakistani family, motor regression began around 6 years of age with loss of head control, sitting, and walking by ~10 years.

Finding 5 — FITM2 variant catalog: predominantly biallelic truncating, with some missense

Reported biallelic FITM2 variants (reference transcript NM_001080472.1):

The Spanish case reported "compound heterozygous novel variants identified by trio-based exome sequencing. She carries the paternally inherited delins variant c.158_161delinsTCAT, p.(Arg53_Asn54delinsLeuIle) and the maternally inherited frameshift variant c.567del, p.(Thr190ProfsTer9)" (PMID: 41758270).

All variants are germline and inherited in an autosomal recessive pattern; the functional consequence is loss of function. Population allele frequencies are extremely low or absent in gnomAD (private/family-specific alleles). A tentative genotype–phenotype gradient suggests truncating variants trend toward more severe disease (early dystonia, profound developmental delay, growth failure), whereas missense variants may be milder — but the data remain limited by small numbers.

Finding 6 — Model organisms recapitulate disease and reveal an essential ER lipid-homeostasis function

• Drosophila melanogaster: RNAi knockdown of the single Fitm ortholog CG10671 recapitulated core Siddiqi features. The authors reported that "downregulation of the single Fitm ortholog, CG10671, in Drosophila melanogaster was pursued using RNA interference. Characteristics of the syndrome, including progressive locomotor impairment, hearing loss and disturbed sensory functions, were recapitulated in Drosophila" (PMID: 28067622) — direct genetic support for causality.
• Mouse (constitutive): Whole-body Fitm2 knockout is embryonic lethal; the gene is essential in mouse and C. elegans.
• Mouse (inducible whole-body): Tamoxifen-inducible knockout causes lethal enteropathy with villus blunting, crypt death, failed enterocyte lipid-droplet formation (TAG accumulates in the ER), bile-acid transporter dysregulation, weight loss, and death within ~2 weeks — "Postnatal Deletion of Fat Storage-inducing Transmembrane Protein 2 (FIT2/FITM2) Causes Lethal Enteropathy" (PMID: 26304121).
• Mouse (hepatocyte-specific): Elevated acyl-CoA, ER stress, liver injury, steatosis (PMID: 36805337).
• Mouse (adipose-specific): Lipodystrophy, insulin resistance (PMID: 30020828).

Notably, no dedicated neuronal or cochlear conditional mouse model reproducing the deafness–dystonia phenotype has yet been reported — a significant gap for mechanistic and preclinical work.

Finding 7 — Allelic dosage series: null alleles cause Siddiqi syndrome, hypomorphic alleles cause milder HSP

A FIT2 activity/dosage spectrum links genotype to phenotype:

FITM2 residual function              Phenotype
──────────────────────────────────────────────────────────
0%  (biallelic null, mouse)      →   Embryonic lethality
0%  (biallelic null/truncating,  →   Siddiqi syndrome
     human)                            (deafness–dystonia–regression)
~20% (hypomorphic missense        →   Hereditary spastic paraplegia
      G100R / null, human)             (milder, later)
100% (wild type)                 →   Normal

A 2025 report established that "Partial loss of FITM2 function causes hereditary spastic paraplegia" (PMID: 39974099). The hypomorphic G100R allele reduces protein to ~20% of wild-type with proportionately decreased diphosphatase activity; in trans with a null allele it produces HSP in two families. Consistent with a continuum, some Siddiqi patients carrying missense alleles (p.Asp151Gly, p.Gly232Arg) show milder/atypical presentations, and spastic paraparesis without dystonia was seen in the Russian family — blurring the boundary between Siddiqi syndrome and FITM2-related HSP.

Finding 8 — Diagnosis, prognosis, and management

Diagnosis is molecular. No specific biomarker or enzyme assay exists; diagnosis is made by whole-exome / trio-exome sequencing confirmed by Sanger sequencing (GTR condition C5231435). Because the phenotype is nonspecific, the disease was historically reached via linkage plus WES (PMID: 28067622) and molecular confirmation of biallelic loss-of-function variants (PMID: 30214770). Supportive investigations include audiometry/BAER (profound bilateral SNHL), brain MRI (often normal early; may show thalamic/red-nucleus T2 signal changes — "These neuroimaging findings may provide new insights into the neurological manifestations of Siddiqi syndrome", PMID: 41758270), and nerve conduction/EMG for sensory neuropathy.

Differential diagnosis includes: neurodegeneration with brain iron accumulation (NBIA; excluded by absence of basal-ganglia iron), Mohr-Tranebjaerg / DDON syndrome (X-linked TIMM8A deafness–dystonia), other syndromic deafness, cerebral palsy, inborn errors of metabolism, and Russell-Silver syndrome (excluded via normal H19 methylation / chromosome 7 UPD).

Prognosis is serious: progressive, chronic, and lifelong, with severe motor disability from dystonia, contractures, and immobility; profound deafness; and growth failure. No cure and no formal survival statistics exist, though some patients have survived into their late 20s–30s.

Management is entirely symptomatic, supportive, and multidisciplinary: cochlear implantation / hearing aids (NCIT: Cochlear Implant), pharmacologic plus physiotherapy for dystonia, nutritional rehabilitation for growth failure, dermatologic care for ichthyosis (emollients), and genetic counseling. No pharmacogenomics, gene therapy, or clinical trials currently exist.

Finding 9 — Pathophysiological causal chain and affected anatomy

The proposed causal chain, upstream to downstream:

Biallelic FITM2 loss of function
│
▼
Loss of ER-luminal fatty acyl-CoA diphosphatase activity (GO:0016787 hydrolase)
│
▼
(a) Accumulation of unbuffered fatty acyl-CoA (CHEBI:37554)
(b) Impaired triglyceride partitioning into lipid droplets
    (GO:0034389 lipid droplet organization; GO:0140042 lipid droplet formation)
│
▼
ER membrane lipid dyshomeostasis, altered ER morphology,
ER stress / unfolded protein response (GO:0034976 response to ER stress)
│
▼
Cellular dysfunction/degeneration in highly metabolically active,
post-mitotic cells (neurons, cochlear hair cells, keratinocytes)
│
▼
Clinical manifestations: SNHL, dystonia, spasticity, sensory neuropathy,
ichthyosis, growth failure

The upstream biochemical defect is defined by "the molecular function of the evolutionarily conserved ER protein FIT2 as a fatty acyl-coenzyme A (CoA) diphosphatase" (PMID: 32915949), and the lipid-droplet arm by the observation that "FITM2 and its paralog FITM1 constitute an evolutionary conserved protein family involved in partitioning of triglycerides into cellular lipid droplets" (PMID: 28067622).

Affected organs/systems and ontology tags:

FITM2 is ubiquitously ER-expressed, but the skin barrier and neurosensory tissues appear most vulnerable in humans. No immune, infectious, or environmental component is implicated — the disease is purely genetic.

Finding 10 — Inheritance and epidemiology

• Inheritance: autosomal recessive (OMIM #618635).
• Penetrance: appears complete in biallelic-variant carriers.
• Expressivity: variable (severity and presence of ichthyosis/neuropathy/seizures/spasticity differ across families).
• Anticipation: none (not a repeat-expansion disorder).
• Germline mosaicism: none reported.
• Consanguinity: a major factor — most families (Pakistani, German, Russian Lezgin, Iranian) are consanguineous with homozygous variants; the US and Spanish cases were compound heterozygous. The index report documented "A consanguineous family from Pakistan was ascertained to have a novel deafness-dystonia syndrome" (PMID: 28067622).
• Founder effects: none established; alleles are largely private/family-specific.
• Carrier frequency: not established; expected very low (variants essentially absent in gnomAD).
• Epidemiology: ultra-rare; ~10–15 patients across ~7 families worldwide as of 2026; no population prevalence/incidence estimates; no dedicated Orphanet prevalence class.
• Sex ratio: ~equal (both sexes affected, consistent with AR).
• Age distribution: infancy (onset ~6 months) to adults in late 20s–30s.

Finding 11 — Final synthesis

Comprehensive review across ~7 reported families (~10–15 patients) and mechanistic studies establishes Siddiqi syndrome as a FITM2 loss-of-function ER lipid-homeostasis disorder with: (1) causation by biallelic FITM2 LoF; (2) a core phenotype of progressive SNHL + generalized dystonia + developmental delay/motor regression + growth failure, with variable ichthyosis, sensory neuropathy, and spasticity; (3) a mechanism of acyl-CoA accumulation and ER stress in post-mitotic neurosensory/epidermal cells; (4) AR inheritance with complete penetrance, variable expressivity, and consanguinity enrichment; (5) an allelic dosage continuum in which hypomorphic alleles cause milder HSP (PMID: 39974099); (6) diagnosis by exome sequencing; and (7) supportive-only management with no cure or trials.

Section-by-Section Report Content

1. Disease Information

Siddiqi syndrome is an autosomal recessive deafness–dystonia disorder caused by biallelic FITM2 variants. Identifiers: OMIM #618635, MONDO:0032842, DOID:0081273; no dedicated Orphanet code; MeSH has no specific descriptor. Synonyms: SIDDIS; FITM2-related deafness–dystonia syndrome. Information is derived from individual case reports, not disease-level EHR resources.

2. Etiology

Causal factor: purely genetic — biallelic loss-of-function variants in FITM2. Genetic risk factor: homozygous or compound-heterozygous LoF FITM2 alleles; consanguinity is the dominant risk context. Environmental/protective factors, gene–environment interactions: none identified — the disorder is fully monogenic with no known modifiers.

3. Phenotypes

See Finding 4 table. Onset is neonatal-to-early-childhood (hearing loss often the first sign; motor regression from ~6 years in the index family). Severity is moderate-to-severe and progressive. Quality-of-life impact is profound — combined deafness, motor disability, and growth failure severely limit daily functioning; no formal QoL instrument has been applied.

4. Genetic/Molecular Information

Causal gene: FITM2 (HGNC:14929). Variant classes: nonsense, frameshift, missense, delins (see Finding 5). Classification: pathogenic/likely pathogenic per ACMG (truncating LoF); some missense are VUS pending functional data. Allele frequency: private/absent in gnomAD. Origin: germline. Consequence: loss of function. Modifier genes/epigenetics/chromosomal abnormalities: none reported.

5. Environmental Information

Not applicable — no environmental, lifestyle, or infectious contributors.

6. Mechanism / Pathophysiology

See Finding 9 causal chain. Pathway: ER lipid metabolism / lipid-droplet biogenesis (not a classical signaling cascade). Cellular processes: ER stress / unfolded protein response, lipid-droplet formation. Protein dysfunction: loss of acyl-CoA diphosphatase activity and TAG-partitioning function. Metabolic change: fatty acyl-CoA accumulation. Subcellular compartments: ER (GO:0005783), lipid droplet (GO:0005811). No immune involvement.

7. Anatomical Structures Affected

Primary: cochlea, basal ganglia/brain, peripheral sensory nerves, skin/epidermis. Secondary: corticospinal tracts (spasticity), whole-body growth. See UBERON/CL table in Finding 9. Lateralization: bilateral/symmetric.

8. Temporal Development

Onset congenital-to-early-childhood, insidious. Course: chronic, progressive with motor regression; lifelong. No remission. Critical window for hearing intervention (cochlear implantation) is early.

9. Inheritance and Population

See Finding 10. Autosomal recessive, complete penetrance, variable expressivity, consanguinity-driven, ultra-rare.

10. Diagnostics

Molecular diagnosis by WES/trio-WES + Sanger (see Finding 8). Supportive: audiometry/BAER, brain MRI, NCS/EMG. Differential: NBIA, DDON/Mohr-Tranebjaerg, other syndromic deafness, cerebral palsy, Russell-Silver syndrome. Screening: cascade carrier testing in families; no newborn screening.

11. Outcome/Prognosis

Serious, progressive, lifelong. Severe motor disability, profound deafness, growth failure. No survival statistics; some survive to late 20s–30s. Complications: contractures, immobility, feeding/nutrition issues.

12. Treatment

Supportive only: cochlear implantation/hearing aids (NCIT: Cochlear Implant), dystonia pharmacotherapy + physiotherapy, nutritional rehabilitation, emollients for ichthyosis, genetic counseling. No pharmacotherapy targeting the primary defect, gene therapy, or trials.

13. Prevention

Genetic counseling, cascade carrier screening, and prenatal/preimplantation genetic testing in known families (primary prevention). No population screening or public-health measures apply.

14. Other Species / Natural Disease

No naturally occurring animal disease reported. Orthologs: mouse Fitm2 (NCBI Gene 84041), Drosophila CG10671. No zoonotic potential. FITM2 is evolutionarily conserved across eukaryotes.

15. Model Organisms

Drosophila RNAi (CG10671) recapitulates locomotor/hearing/sensory phenotype; mouse conditional knockouts (liver, adipose, intestine) confirm ER stress and acyl-CoA accumulation; constitutive mouse KO is embryonic lethal. Gap: no cochlear/neuronal conditional mouse model. Resources: MGI, FlyBase.

Mechanistic Model / Interpretation

Siddiqi syndrome is best understood as a cell-autonomous ER lipid-homeostasis failure that preferentially injures post-mitotic, metabolically demanding cell types. The FITM2 protein performs two intertwined jobs in the ER: (1) as a fatty acyl-CoA diphosphatase, it hydrolyzes surplus fatty acyl-CoA to acyl-4′-phosphopantetheine, thereby buffering a reactive lipid species; and (2) as a lipid-droplet biogenesis factor, it binds triglyceride and partitions it into nascent cytosolic lipid droplets. Loss of both alleles removes both functions simultaneously.

The convergent downstream consequence is ER membrane stress. Unbuffered acyl-CoA is amphipathic and detergent-like; its accumulation, combined with the inability to sequester triglyceride into droplets, distorts ER membrane structure and triggers the unfolded protein response. In cells that cannot divide to dilute damage and that depend on continuous high-flux membrane and energy metabolism — cochlear hair cells, central neurons of the basal ganglia and corticospinal tracts, peripheral sensory neurons, and epidermal keratinocytes maintaining the skin barrier — this chronic stress manifests as progressive degeneration. This cell-type vulnerability map explains the otherwise puzzling combination of deafness (hair cells), dystonia and spasticity (basal ganglia and corticospinal neurons), sensory neuropathy (dorsal root ganglion neurons), and ichthyosis (barrier-lipid–dependent keratinocytes).

The allelic dosage series is the most elegant piece of the model. Mouse constitutive knockout is embryonic lethal, demonstrating an absolute developmental requirement. In humans, complete biallelic loss is compatible with life but produces the severe, multi-system Siddiqi phenotype. Retaining ~20% of FITM2 activity (the hypomorphic G100R allele) shifts the phenotype to a milder, more slowly progressive hereditary spastic paraplegia. The clinical spectrum therefore maps onto a continuum of residual enzyme activity, with the threshold for each organ system's vulnerability differing — the auditory and extrapyramidal systems appear most sensitive to complete loss, while partial loss chiefly compromises the corticospinal tract.

Evidence Base

The evidence base is internally consistent: human genetics (7 families), invertebrate genetics (Drosophila), mammalian conditional knockouts (mouse liver, adipose, intestine), and biochemistry (enzymology, structural topology) all converge on the same molecular lesion. No paper in the reviewed literature challenges the FITM2-loss-of-function causal model.

Limitations and Knowledge Gaps

1. Extremely small sample size. With only ~10–15 patients from ~7 families, all phenotype frequencies, genotype–phenotype correlations, and prognostic statements are based on case reports, not cohorts. The tentative severity gradient (truncating > missense) is under-powered.
2. No neurosensory animal model. No conditional mouse knockout targeting cochlear hair cells or CNS/PNS neurons exists, so the direct mechanistic link between FITM2 loss and the deafness–dystonia phenotype remains inferred rather than experimentally demonstrated in a mammal.
3. No biomarker or functional assay. Diagnosis relies solely on sequencing; there is no metabolite, protein, or enzyme-activity biomarker to confirm pathogenicity of missense variants or to monitor disease.
4. Uncertain phenotype boundaries. The overlap between complete-loss Siddiqi syndrome and hypomorphic-allele HSP is not fully resolved; whether these are one continuum or distinct entities has clinical counseling implications.
5. No natural history data. Survival, progression rate, and quality-of-life measures are anecdotal. No registry, longitudinal cohort, or formal QoL instrument (EQ-5D, SF-36, PROMIS) has been applied.
6. No Orphanet code / prevalence class, and no epidemiological estimates of prevalence, incidence, or carrier frequency.
7. Human tissue mechanism unverified. Acyl-CoA accumulation and ER stress are documented in mouse liver/adipose/gut and in vitro, but not directly in affected human neurosensory or epidermal tissue.

Proposed Follow-up Experiments / Actions

1. Generate a neurosensory conditional mouse model — e.g., Atoh1-Cre (hair cells) or pan-neuronal/Nestin-Cre Fitm2 conditional knockout — to test whether FITM2 loss recapitulates progressive SNHL and dystonia, and to establish a preclinical platform.
2. Establish patient-derived iPSC models differentiated into cochlear organoids, cortical/striatal neurons, and keratinocytes to directly measure acyl-CoA accumulation, ER stress markers (BiP, CHOP, spliced XBP1), and lipid-droplet defects in the affected human cell types.
3. Develop a functional assay for variant classification — a cell-based FIT2 acyl-CoA diphosphatase activity or lipid-droplet-rescue assay — to reclassify missense VUS and quantify residual activity, directly testing the dosage-series model.
4. Create an international patient registry (via GeneMatcher/MatchMaker Exchange) to aggregate natural-history data, standardize phenotyping with HPO, apply QoL instruments, and derive prevalence/prognostic estimates.
5. Systematic MRI characterization across all known patients to determine whether thalamic/red-nucleus signal changes are a consistent, diagnostically useful feature.
6. Lipidomic/metabolomic profiling of patient plasma, fibroblasts, and (where available) tissue to search for a diagnostic/monitoring biomarker (e.g., accumulated acyl-CoA species or altered barrier lipids).
7. Formally define the Siddiqi–HSP spectrum by pooling all FITM2 variants with residual-activity measurements and correlating with organ-specific severity, to guide genetic counseling.
8. Assign an Orphanet ORPHA code and complete the ontology cross-references to improve discoverability and registry linkage.

Report compiled from a 5-iteration autonomous investigation: 11 confirmed findings, 29 papers reviewed. Evidence types span human clinical case reports, model-organism genetics (Drosophila, mouse, C. elegans), in vitro biochemistry, and structural/computational analysis.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• DOID:0081273 (3 mentions) - the report calls it "Disease Ontology"; DOID calls it Siddiqi syndrome
• MONDO:0032842 (2 mentions) - the report calls it "MONDO"; MONDO calls it Siddiqi syndrome
• HP:0001332 (1 mention) - the report calls it "Dystonia (generalized/truncal/limb)"; HP calls it Dystonia
• HP:0001250 (1 mention) - the report calls it "Seizures; chronic diarrhea"; HP calls it Seizure

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0000407 (1 mention) - the report calls it "Progressive sensorineural hearing loss"; HP calls it Sensorineural hearing impairment, and lists "Sensorineural hearing loss" among its other names
• HP:0002376 (1 mention) - the report calls it "Regression of motor skills"; HP calls it Developmental regression, and lists "Psychomotor regression, progressive" among its other names
• HP:0008064 (1 mention) - the report calls it "Ichthyosis-like skin (esp. lower limbs)"; HP calls it Ichthyosis, and lists "Ichthyotic skin" among its other names
• HP:0001761 (1 mention) - the report calls it "Contractures / pes cavus"; HP calls it Pes cavus
• UBERON:0002420 (1 mention) - the report calls it "Basal ganglion (→ dystonia)"; UBERON calls it basal ganglion
• UBERON:0001844 (1 mention) - the report calls it "Cochlea (→ SNHL)"; UBERON calls it cochlea
• UBERON:0001780 (1 mention) - the report calls it "Peripheral nerve (→ sensory neuropathy)"; UBERON calls it spinal nerve, and lists "spinal nerve tree" among its other names
• UBERON:0001003 (1 mention) - the report calls it "Skin / epidermis (→ ichthyosis)"; UBERON calls it skin epidermis
• CL:0000855 (1 mention) - the report calls it "Cochlear hair cell"; CL calls it sensory hair cell